Scarica l'app Stockscreener
7.32
1.88%
-0.14
Dopo l'orario di chiusura:
7.30
-0.02
-0.27%
Precedente Chiudi:
$7.46
Aprire:
$7.33
Volume 24 ore:
193.11K
Relative Volume:
0.51
Capitalizzazione di mercato:
$285.02M
Reddito:
$5.74M
Utile/perdita netta:
$-166.12M
Rapporto P/E:
-1.831
EPS:
-3.9978
Flusso di cassa netto:
$-131.64M
1 W Prestazione:
+5.32%
1M Prestazione:
+6.24%
6M Prestazione:
-33.58%
1 anno Prestazione:
+38.90%
Intervallo 1D:
$7.25
$7.56
Intervallo di 1 settimana:
$6.93
$7.765
Portata 52W:
$5.02
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
7.32 | 290.47M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Oppenheimer | Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
(TRDA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Analysts Lower Earnings Estimates for TRDA - marketbeat.com
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares By Investing.com - Investing.com India
Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock - tipranks.com
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares - Investing.com India
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock - Investing.com
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620 - Bitget
Kush Parmar Sells 92,444 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares - MarketBeat
Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M - Stock Titan
Entrada Therapeutics Inc (TRDA) Stock News Today - TradingKey
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Entrada Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Entrada Therapeutics Submits Q2 2026 10-Q Report to SEC - Kalkine Media
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entrada Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary - TradingView
Entrada Therapeutics Reports Second Quarter 2026 Financial Results - The Manila Times
Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M - TradingView
Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline - Stock Titan
Entrada Therapeutics director Kush Parmar sells $807,027 in shares By Investing.com - Investing.com India
5am Ventures V sells $807,027 of Entrada Therapeutics stock By Investing.com - Investing.com India
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
5am Ventures V sells $807,027 of Entrada Therapeutics stock - Investing.com
Entrada Therapeutics director Kush Parmar sells $807,027 in shares - Investing.com
Ventures L.P. 5Am Sells 114,756 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - marketbeat.com
Form 4 Entrada Therapeutics Inc For: 4 August By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing - marketscreener.com
Entrada Therapeutics (TRDA) holder sells shares, still reports 1.09M stake - stocktitan.net
Liquidity Mapping Around (TRDA) Price Events - Stock Traders Daily
Entrada Therapeutics Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Form 144 ENTRADA THERAPEUTICS For: 30 July By Investing.com - Investing.com Canada
Entrada Therapeutics, Inc. SEC Filing (Jul 30, 2026) - Stock Titan
Entrada Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRDA - TradingView
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entrada Therapeutics Inc (TRDA) Cash Flow - TradingKey
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entrada Therapeutics (TRDA) Climbs 5.47%: Support and Resistance in FocusSmart Money Flow Stocks - dars.gov.et
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Balance Sheet - TradingKey
Entrada Therapeutics Inc|Price:5.850|Chg%:-0.200 - TradingKey
Entrada Therapeutics (TRDA) Slides 3.33% as Stock Tests Key Support LevelsHigh Beta Stocks - dars.gov.et
Why (TRDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Entrada Therapeutics Inc Azioni (TRDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PARMAR KUSH | Director |
Aug 07 '26 |
Sale |
6.85 |
52,317 |
358,371 |
2,783,781 |
| PARMAR KUSH | Director |
Aug 06 '26 |
Sale |
7.00 |
10,494 |
73,458 |
2,836,098 |
| 5AM Ventures V, L.P. | 10% Owner |
Aug 07 '26 |
Sale |
6.85 |
52,317 |
358,371 |
2,783,781 |
| 5AM Ventures V, L.P. | 10% Owner |
Aug 06 '26 |
Sale |
7.00 |
10,494 |
73,458 |
2,836,098 |
| 5AM Ventures V, L.P. | 10% Owner |
Jul 30 '26 |
Sale |
6.93 |
114,756 |
795,259 |
2,848,310 |
| 5AM Ventures V, L.P. | 10% Owner |
Jul 31 '26 |
Sale |
6.85 |
1,718 |
11,768 |
2,846,592 |
| PARMAR KUSH | Director |
Jul 30 '26 |
Sale |
6.93 |
114,756 |
795,259 |
2,848,310 |
| PARMAR KUSH | Director |
Jul 31 '26 |
Sale |
6.85 |
1,718 |
11,768 |
2,846,592 |
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):